COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica: First-Quarter 2026 Revenue Conference Call Invitation
10/04/2026
First-Quarter 2026 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our First-Quarter 2026 Revenue [...]
EssilorLuxottica: First-Quarter 2026 Revenue Conference Call Invitation
10/04/2026
First-Quarter 2026 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our First-Quarter 2026 Revenue [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 mars 2026
10/04/2026
Nombre total de droits de vote et d’actions composant le capital social au 31 mars 2026 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 31, 2026
10/04/2026
Disclosure of Share Capital and Voting Rights Outstanding as of March 31, 2026 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Suja Life Announces Filing of Registration Statement for Proposed Initial Public Offering
10/04/2026
OCEANSIDE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Suja Life, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to the [...]
Matricis.ai Launches First U.S. Clinical Pilot of EndomAI for AI-Assisted Detection of Endometriosis with SimonMed
10/04/2026
Collaboration marks the first clinical pilot of AI-assisted MRI analysis for endometriosis. Paris, France, April 10, 2026 (GLOBE NEWSWIRE) -- Matricis.ai, a healthcare technology company developing artificial [...]
Humber River Health Renames Wilson Site Hennick Humber Hospital Following Transformational $50 Million Gift
10/04/2026
Landmark philanthropic investment from the Hennick Family Foundation will accelerate innovation and patient care at North America’s first fully digital hospital TORONTO, April 10, 2026 (GLOBE NEWSWIRE) -- Humber River [...]
EUROBIO SCIENTIFIC : RESULTAT ANNUEL 2025
10/04/2026
RESULTAT ANNUEL 2025 Progression du chiffre d’affaires annuel de 9% à 168 M€ Déploiement de la stratégie du Groupe : Ventes des produits propriétaires en hausse de 20%, à 35% du Chiffre d’affaires Internationalisation [...]
EUROBIO SCIENTIFIC : 2025 ANNUAL RESULTS
10/04/2026
2025 ANNUAL RESULTS Annual revenue up 9% to €168 million Roll-out of the Group’s strategy: Sales of proprietary products up 20%, accounting for 35% of revenue Internationalisation: 42% of revenue generated outside [...]
Unyte Health Acquires Vital Links and Vital Sounds, Developers of Therapeutic Listening®
10/04/2026
DENVER, April 10, 2026 (GLOBE NEWSWIRE) -- Unyte Health, a leader in listening therapy interventions, is proud to announce that Vital Links and Vital Sounds have officially joined its growing family of clinical [...]
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
10/04/2026
Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium MONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space
10/04/2026
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by AINewsWire ("AINW"), one of 75+ brands within the [...]
NeurAxis, Inc. Announces Preferred Stock Dividend
10/04/2026
CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating [...]
Clariane annonce le succès de son offre de 500 millions d’euros d’obligations senior
10/04/2026
NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE, AU CANADA, AU JAPON OU EN AUSTRALIE, OU DANS TOUTE AUTRE JURIDICTION OU IL EST ILLÉGAL DE DIFFUSER, DE PUBLIER OU DE [...]
LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
10/04/2026
LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect® NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- [...]
Clariane announces the success of its offering of €500 million of senior notes
10/04/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Clariane [...]
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
10/04/2026
Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections, and reduced vaccine efficacy HOUSTON, April 10, 2026 (GLOBE [...]
BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications
10/04/2026
Targets $81B command-and-control and video analytics markets by 2030, driven by real-time situational awareness in defense environments NETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc [...]
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
10/04/2026
Financing secures path to first NDA submission for buntanetap 6-Month symptomatic data readout anticipated Q1 2027 Alzheimer’s disease Phase 3 trial 75% enrolled Parkinson's disease open-label study 28% enrolled MALVERN [...]

Pages